ANI Pharmaceuticals Inc  

(Public, NASDAQ:ANIP)   Watch this stock  
Find more results for NASDAQ:BPAX
61.94
+1.55 (2.57%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 60.42 - 62.51
52 week 19.90 - 71.78
Open 60.42
Vol / Avg. 309,848.00/402,690.00
Mkt cap 705.38M
P/E 24.97
Div/yield     -
EPS 2.48
Shares 11.39M
Beta 2.48
Inst. own 60%
May 4, 2015
Q1 2015 ANI Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 9, 2015
ANI Pharmaceuticals Inc at ROTH Conference
Feb 19, 2015
Q4 2014 ANI Pharmaceuticals Inc Earnings Call
Feb 19, 2015
Q4 2014 ANI Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 99.85% 51.36%
Operating margin 51.21% 35.74%
EBITD margin - 42.67%
Return on average assets 45.38% 18.65%
Return on average equity 70.21% 31.63%
Employees 92 -
CDP Score - -

Address

210 W Main St
BAUDETTE, MN 56623-2467
United States - Map
+1-218-6343500 (Phone)
+1-218-6343540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173, 00 square feet, the Company manufactures oral solid dose products, as well as liquids and topicals, including narcotics. The Company performs contract manufacturing for other pharmaceutical companies. It has launched three products and has 11 products in development. The Company´┐Żs targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. The Company is positioned to develop and manufacture niche oncolytic (anti-cancer) drugs due to the capabilities of the Company's containment facility and its expertise in manufacturing segregation.

Officers and directors

Robert E. Brown Jr. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Arthur S. Przybyl President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Charlotte C. Arnold Chief Financial Officer, Vice President
Age: 51
Bio & Compensation  - Reuters
James G. Marken Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
David J. Sullivan Ph.D. Vice President - Quality Operations
Bio & Compensation  - Reuters
Robert W. Schrepfer Vice President - New Business Development and Contract Manufacturing
Age: 42
Bio & Compensation  - Reuters
Thomas A. Penn Director
Age: 68
Bio & Compensation  - Reuters
Fred H. Holubow Independent Director
Age: 75
Bio & Compensation  - Reuters
Ross J. Mangano Independent Director
Age: 68
Bio & Compensation  - Reuters
Tracy L. Marshbanks Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters